Buy and Cell: News from the world of biotech

By Jonathan Jackson. Published at Sep 3, 2018, in Opinion

Growing up, I never had any real interest in science or technology.

(A bit rich coming from the person bringing you this biotech-themed newsletter I admit, but it’s true.)

I was never any good at maths. And physics — forget about it.

I did have a passing interest in biology, but that was short-lived after a chemical mix up sent a spark from the test tube down the front of my school shirt, incinerating the birthmark on my chest. I don’t know if that says more about my inability as a scientist, or the lack of safety in schools in the 1980s.

Probably a bit of both. But I digress...

What I have developed as time has gone by is an interest in research and development for various cancers. Cancer has taken the lives of several family friends and I have a young niece currently in remission.

Heart disease and diabetes also run in the family. So I keep a keen eye on any progress made by biotech and medtech companies with regards to potential cures and preventions for a whole range of conditions.

Some of those companies have already featured heavily in Finfeed and include Respiri, Prescient (see below), Neurotech, Immuron, Rhythm Biosciences and more.

Medical diagnostics innovator Rhythm Biosciences is in the process of preparing reagents for its ColoSTATTM blood test, which tests for colorectal cancer. Prescient Therapeutics is working in the field of breast cancer, bringing two novel cancer drugs to the table.

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Facebook
Twitter
LinkedIn